Gera

• A trial to learn how well Dato-DXd and rilvegostomig work and how safe they are in participants with stage I adenocarcinoma non-small cell l … Pending
  2024-512195-35-00 5 Stage I adenocarcinoma non-small cell lung cancer (NSCLC) with ctDNA-p
• Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced br … Pending
  2024-518026-32-00 5 Invasive Breast Cancer
• A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease Pending
  2025-521113-13-00 10 Early Parkinson’s Disease
• A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder. Pending
  2025-524488-18-00 4 Muscle-invasive Bladder Cancer
• A clinical trial of V940 with or without MK-3475A in people with non-small cell lung cancer (V940-014) Recruiting
  2025-522643-18-00 5 2026-06-16 Stage I NSCLC
• A Study of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50% Recruiting
  2025-523586-18-00 5 2026-06-11 Non-Small Cell Lung Cancer
• ROSETTA Breast-01: The effects and safety of pumitamig in patients with triple-negative breast cancer Recruiting
  2025-521884-12-00 5 2026-03-19 First line triple-negative breast cancer (TNBC)
• A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK10 … Recruiting
  2024-512659-19-00 10 2025-03-31 Advanced Melanoma
• A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better than Anti-PD1 Alone in Adult Participants with Resectable Stage 3 or 4 … Recruiting
  2022-502825-17-00 4 2024-10-07 Melanoma
• Clinical trial that compares MK-2870 with or without pembrolizumab to chemotherapy in people with breast cancer that cannot be surgically re … Recruiting
  2023-504918-29-00 5 2024-08-22 Hormone receptor positive breast cancer
• Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica … Recruiting
  2023-506548-18-00 10 2022-11-10 Dermatitis atopic
• Evaluation of Niraparib alone compared to the combination of Niraparib and Bevacizumab in patients receiving chemotherapy for newly diagnose … Recruiting
  2024-516066-11-00 5 2022-08-31 Patients with newly diagnosed, histologically confirmed, primary advan
• A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or … Recruiting
  2025-523461-17-01 5 2026-06-01 LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
• A Phase 3 Study of I-DXd in Subjects with Relapsed SCLC Recruiting
  2023-509628-16-00 5 2026-05-07 Small Cell Lung Cancer (SCLC)
• Safety and efficacy of BNT327, an investigational therapy, in combination with chemotherapy for patients with untreated small-cell lung canc … Recruiting
  2024-515765-34-00 5 2026-02-04 English First-line extensive-stage small-cell lung cancer (ES-SCLC)
• Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting
  2024-515764-31-00 10 2025-06-13 Non-small cell lung cancer
• Study of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Unt … Recruiting
  2024-515698-85-00 5 2025-06-12 Locally Advanced or Metastatic Non-small Cell Lung Cancer
• A trial to learn if Dato-DXd with rilvegostomig, or rilvegostomig alone, is safe and works compared with pembrolizumab in people who have ad … Recruiting
  2023-505077-32-00 5 2025-01-28 Locally-advanced or metastatic non-squamous non-small cell lung cancer
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting
  2024-512279-10-00 5 2024-11-25 Triple Negative Breast Cancer
• Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting
  2023-508012-35-00 5 2024-10-02 Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB
• Pembrolizumab With or Without Maintenance MK‑2870 in Metastatic Squamous NSCLC Recruiting
  2023-510128-66-00 5 2024-09-02 Participants with treatment-naïve metastatic squamous Non-small Cell L
• A clinical study to compare MK-2870 with pembrolizumab to pembrolizumab alone in people with lung cancer (MK-2870-007) Recruiting
  2023-503376-24-00 5 2024-03-20 Metastatic non-small cell lung cancer (NSCLC)
• Pan tumor Roll Over Study Recruiting
  2023-506914-32-00 4 2020-05-05 Pan tumor
• Randomized, double-blind, placebo-controlled, multi-centre trial to evaluate the efficacy, safety and tolerability of oral treatment with li … Recruiting
  2024-512104-19-00 6 2019-11-19 Irritable Bowel Syndrome

Showing 1–24 of 56 trials